Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
29
07
2020
accepted:
12
10
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
epublish
Résumé
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9-12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment. We conducted a prospective study of a shorter standardised MDR-TB regimen in Karakalpakstan, Uzbekistan. Consecutive adults and children with confirmed rifampicin-resistant pulmonary TB were enrolled between September 1, 2013 and March 31, 2015; exclusions included prior treatment with second-line anti-TB drugs, and documented resistance to ofloxacin or to two second-line injectable agents. The primary outcome was recurrence-free cure at 1 year following treatment completion. Of 146 enrolled patients, 128 were included: 67 female (52.3%), median age 30.1 (interquartile range 23.8-44.4) years. At the end of treatment, 71.9% (92 out of 128) of patients achieved treatment success, with 68% (87 out of 128) achieving recurrence-free cure at 1 year following completion. Unsuccessful outcomes during treatment included 22 (17.2%) treatment failures with fluoroquinolone-resistance amplification in 8 patients (8 out of 22, 36.4%); 12 (9.4%) lost to follow-up; and 2 (1.5%) deaths. Recurrence occurred in one patient. Fourteen patients (10.9%) experienced serious adverse events. Baseline resistance to both pyrazinamide and ethambutol (adjusted OR 6.13, 95% CI 2.01; 18.63) and adherence <95% (adjusted OR 5.33, 95% CI 1.73; 16.36) were associated with unsuccessful outcome in multivariable logistic regression. Overall success with a standardised shorter MDR-TB regimen was moderate with considerable treatment failure and amplification of fluoroquinolone resistance. When introducing standardised shorter regimens, baseline drug susceptibility testing and minimising missed doses are critical. High rates globally of pyrazinamide, ethambutol and ethionamide resistance raise questions of continued inclusion of these drugs in shorter regimens in the absence of drug susceptibility testing-confirmed susceptibility.
Sections du résumé
BACKGROUND
BACKGROUND
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9-12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment. We conducted a prospective study of a shorter standardised MDR-TB regimen in Karakalpakstan, Uzbekistan.
METHODS
METHODS
Consecutive adults and children with confirmed rifampicin-resistant pulmonary TB were enrolled between September 1, 2013 and March 31, 2015; exclusions included prior treatment with second-line anti-TB drugs, and documented resistance to ofloxacin or to two second-line injectable agents. The primary outcome was recurrence-free cure at 1 year following treatment completion.
RESULTS
RESULTS
Of 146 enrolled patients, 128 were included: 67 female (52.3%), median age 30.1 (interquartile range 23.8-44.4) years. At the end of treatment, 71.9% (92 out of 128) of patients achieved treatment success, with 68% (87 out of 128) achieving recurrence-free cure at 1 year following completion. Unsuccessful outcomes during treatment included 22 (17.2%) treatment failures with fluoroquinolone-resistance amplification in 8 patients (8 out of 22, 36.4%); 12 (9.4%) lost to follow-up; and 2 (1.5%) deaths. Recurrence occurred in one patient. Fourteen patients (10.9%) experienced serious adverse events. Baseline resistance to both pyrazinamide and ethambutol (adjusted OR 6.13, 95% CI 2.01; 18.63) and adherence <95% (adjusted OR 5.33, 95% CI 1.73; 16.36) were associated with unsuccessful outcome in multivariable logistic regression.
CONCLUSIONS
CONCLUSIONS
Overall success with a standardised shorter MDR-TB regimen was moderate with considerable treatment failure and amplification of fluoroquinolone resistance. When introducing standardised shorter regimens, baseline drug susceptibility testing and minimising missed doses are critical. High rates globally of pyrazinamide, ethambutol and ethionamide resistance raise questions of continued inclusion of these drugs in shorter regimens in the absence of drug susceptibility testing-confirmed susceptibility.
Identifiants
pubmed: 33585652
doi: 10.1183/23120541.00537-2020
pii: 00537-2020
pmc: PMC7869592
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©ERS 2021.
Déclaration de conflit d'intérêts
Conflict of interest: P. du Cros reports other funded work from TB Alliance for introduction of pretomanid, outside the submitted work. Conflict of interest: A. Khamraev has nothing to disclose. Conflict of interest: Z. Tigay has nothing to disclose. Conflict of interest: T. Abdrasuliev has nothing to disclose. Conflict of interest: J. Greig has nothing to disclose. Conflict of interest: G. Cooke has nothing to disclose. Conflict of interest: K. Herboczek has nothing to disclose. Conflict of interest: T. Pylypenko has nothing to disclose. Conflict of interest: C. Berry has nothing to disclose. Conflict of interest: A. Ronnachit has nothing to disclose. Conflict of interest: D. Lister has nothing to disclose. Conflict of interest: S. Dietrich has nothing to disclose. Conflict of interest: C. Ariti has nothing to disclose. Conflict of interest: K. Safaev has nothing to disclose. Conflict of interest: B-T. Nyang'wa has nothing to disclose. Conflict of interest: N. Parpieva has nothing to disclose. Conflict of interest: M. Tillashaykhov has nothing to disclose. Conflict of interest: J. Achar has nothing to disclose.
Références
Glob Public Health. 2014;9(9):1107-16
pubmed: 25035943
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):436-40
pubmed: 23254152
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031
pubmed: 27685538
Lancet. 2016 Nov 5;388(10057):2234
pubmed: 27825500
Ann Noninvasive Electrocardiol. 2003 Apr;8(2):170
pubmed: 12848800
Ann Noninvasive Electrocardiol. 2003 Oct;8(4):343-51
pubmed: 14516292
BMC Infect Dis. 2016 Jul 28;16:362
pubmed: 27465783
Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94
pubmed: 25216832
Lancet Glob Health. 2019 Jun;7(6):e706
pubmed: 31005492
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751411
J Clin Microbiol. 2006 Mar;44(3):688-92
pubmed: 16517840
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331043
Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92
pubmed: 20442432
Eur Respir J. 2017 Jul 20;50(1):
pubmed: 28729476
Lancet. 2016 Jun 18;387(10037):2486-7
pubmed: 27353670
Clin Infect Dis. 2019 Oct 30;69(10):1809-1811
pubmed: 30901021
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331031
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245
pubmed: 29471899
N Engl J Med. 2019 Mar 28;380(13):1201-1213
pubmed: 30865791
Int J Tuberc Lung Dis. 2015 May;19(5):517-24
pubmed: 25868018
Nephron. 1976;16(1):31-41
pubmed: 1244564
PLoS One. 2013 Nov 06;8(11):e78364
pubmed: 24223148
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25
pubmed: 29149917
Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029
pubmed: 27739887
Clin Infect Dis. 2016 Feb 15;62(4):418-430
pubmed: 26508515
Cochrane Database Syst Rev. 2014 Oct 29;(10):CD010705
pubmed: 25353401
Trop Med Int Health. 2018 Jun;23(6):668-677
pubmed: 29691959